<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638182</url>
  </required_header>
  <id_info>
    <org_study_id>10-3-018</org_study_id>
    <nct_id>NCT01638182</nct_id>
  </id_info>
  <brief_title>Biocomparison Study</brief_title>
  <official_title>Comparison of Effects of Nutritional Doses Vitamin K1 and K2 on Carboxylation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of two vitamin K-forms on carboxylation of the vitamin K-dependent proteins&#xD;
      osteocalcin and matrix-gla protein will be compared after supplementing these vitamins in a&#xD;
      nutritional dose range.&#xD;
&#xD;
      The investigators hypothesized that MK-7 is more effective than K1 at a dose comparable to&#xD;
      the RDA of vitamin K.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin K is a group name for the naturally occurring phylloquinone (K1) and menaquinones&#xD;
      (MK-n; K2). The latter can be subdivided into the short-chain (e.g. MK-4) and the long-chain&#xD;
      (e.g. MK-7, MK-8, and MK-9) menaquinones. Earlier studies have shown that high vitamin K&#xD;
      intake leads to improved bone and vascular health by increased carboxylation of vitamin&#xD;
      K-dependent proteins in these tissues. In the dietary range, MK-7 has been suggested to be&#xD;
      the most effective cofactor for the carboxylation of Gla-proteins, such as osteocalcin (OC)&#xD;
      and matrix-Gla protein (MGP).Until now, no randomized controlled trial has compared the&#xD;
      efficacy of K1 versus MK-7 in a nutritional dose range. The investigators are therefore&#xD;
      interested to compare the effects of K1 and MK-7 on OC and MGP carboxylation after&#xD;
      supplementing these vitamins at a dose not exceeding the RDA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>carboxylation of osteocalcin</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective of the study is to compare the effects of K1 and MK-7 on circulating ucOC levels after supplementing these vitamins at a nutritional dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>carboxylation of matrix-gla protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objective of the study is to compare the effects of K1 and MK-7 on circulating ucMGP, which is emerging as a biomarker of arterial calcification.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Bone Health</condition>
  <condition>Vascular Health</condition>
  <arm_group>
    <arm_group_label>vitamin K1 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K2-capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>27 participants received for 3 months 1 placebo capsule per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>27 participants received for three months 1 placebo capsule per day</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K1-capsules</intervention_name>
    <description>27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day</description>
    <arm_group_label>vitamin K1 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2-capsules</intervention_name>
    <description>27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.</description>
    <arm_group_label>Vitamin K2-capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women, aged between 20-80 years&#xD;
&#xD;
          -  Normal body weight and height (18.5 kg/m2 &lt; BMI &lt; 30 kg/m2)&#xD;
&#xD;
          -  Stable body weight (weight gain or loss &lt; 3 kg in past 3 mo)&#xD;
&#xD;
          -  Written consent to take part in the study&#xD;
&#xD;
          -  Agreement to adhere to dietary restrictions required by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abuse of drugs and/or alcohol&#xD;
&#xD;
          -  Use of vitamin supplements containing vitamin K&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  (a history of) metabolic or gastrointestinal diseases, e.g. hepatic or renal&#xD;
             disorders, osteoporosis&#xD;
&#xD;
          -  Chronic degenerative and/or inflammatory diseases, e.g. diabetes mellitus, cancer,&#xD;
             cardiovascular disease&#xD;
&#xD;
          -  Use of oral anticoagulants, drugs or hormones that influence bone metabolism&#xD;
&#xD;
          -  Corticoid treatment&#xD;
&#xD;
          -  Subjects with anaemia or subjects who recently donated blood or plasma&#xD;
&#xD;
          -  Systemic treatment or topical treatment likely to interfere with coagulation&#xD;
             metabolism (salicylates, antibiotics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees Vermeer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VitaK BV Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaK BV / Maastricht University Medicial Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phylloquinone,</keyword>
  <keyword>menaquinone-7</keyword>
  <keyword>vitamin K-status</keyword>
  <keyword>efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin K 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

